• Home
  •  / Vertex Pharmaceuticals

Vertex Pharmaceuticals

OverviewSuggest Edit

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
TypePublic
Founded1989
HQBoston, USMap
Websitevrtx.com
Employee Ratings3.3More
View Jobs (159)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)3,000(+20%)
Job Openings159
Revenue (FY, 2019)$4.2 B(+37%)
Share Price (Sept 2020)$264.8 (+3%)
Cybersecurity ratingDMore

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Jeffrey Leiden

Executive Chairman
Reshma Kewalramani

Reshma Kewalramani

Chief Executive Officer, President & Director
Sangeeta N. Bhatia

Sangeeta N. Bhatia

Director
David Altshuler

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer
Carmen Bozic

Carmen Bozic

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Stuart A. Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Commercial Officer
Show more

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations
Boston, US (HQ)
50 Northern Ave
San Diego, US
3215 Merryfield Row
Washington, US
1050 K St NW
Watertown, US
490 Arsenal Way #110
St Leonards, AU
level 3 suite 3/601 Pacific Hwy
Wien, AT
Lehrbachgasse 13
Show all (27)

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Revenue

Vertex Pharmaceuticals's revenue was reported to be $4.16 b in FY, 2019
USD

Revenue (Q2, 2020)

1.5b

Market capitalization (14-Sept-2020)

72.7b

Closing stock price (14-Sept-2020)

264.8

Cash (30-Jun-2020)

4.8b

EV

68.4b
Vertex Pharmaceuticals's current market capitalization is $72.7 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

143.4m1.4b1.5b1.2b580.4m1.0b1.7b2.5b3.0b4.2b

Revenue growth, %

(52%)78%65%

Cost of goods sold

63.6m236.7m89.0m39.7m117.2m206.8m272.7m409.5m547.8m

Gross profit

1.3b1.3b1.1b540.7m915.2m1.5b2.2b2.6b3.6b
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

22.4m31.6m23.8m73.7m114.4m659.2m438.7m418.3m336.0m328.4m310.8m221.7m118.5m138.4m179.0m138.5m166.1m309.8m398.1m431.6m413.8m714.7m544.1m578.2m640.8m752.2m784.5m858.4m941.3m949.8m1.5b1.5b

Cost of goods sold

5.4m35.3m25.9m104.5m30.7m31.0m24.7m20.0m8.6m9.7m10.2m9.4m15.4m30.3m49.8m44.2m53.2m46.2m70.5m72.2m71.6m104.4m111.3m95.1m135.7m131.9m162.5m

Gross profit

109.0m623.9m412.8m313.8m305.3m297.4m286.1m201.7m109.9m128.8m168.8m129.1m150.7m279.5m348.3m387.5m360.6m668.5m473.6m506.0m569.2m647.8m673.3m763.3m805.6m817.9m1.4b

Gross profit Margin, %

95%95%94%75%91%91%92%91%93%93%94%93%91%90%87%90%87%94%87%88%89%86%86%89%86%86%89%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

243.2m475.3m489.4m569.3m625.3m714.8m1.2b1.7b2.7b3.1b

Accounts Receivable

12.5m183.1m143.3m85.5m76.0m177.6m201.1m281.3m409.7m633.5m

Prepaid Expenses

14.9m24.7m23.8m52.6m50.9m165.6m140.8m213.5m

Inventories

112.4m30.5m14.1m30.8m57.2m77.6m111.8m124.4m167.5m
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

396.5m337.6m569.9m446.5m458.2m542.5m267.9m454.1m436.9m379.1m531.2m583.2m424.0m420.6m718.6m664.9m870.5m756.3m604.2m605.9m719.7m1.0b1.2b1.4b2.0b2.1b2.5b2.9b3.3b3.4b3.6b4.8b

Accounts Receivable

7.9m3.5m5.0m5.6m96.0m445.7m232.2m185.6m139.6m194.1m164.9m120.3m59.9m81.8m114.3m80.3m94.5m165.3m181.9m189.4m182.2m208.0m247.9m263.5m327.3m393.4m379.8m438.3m464.9m443.3m845.3m791.8m

Prepaid Expenses

23.2m35.4m40.5m35.1m47.8m43.2m41.1m35.0m34.4m41.3m62.6m53.3m63.4m55.9m56.3m61.0m128.5m107.1m152.2m109.9m122.7m118.7m130.0m151.8m175.1m223.6m232.6m

Inventories

17.8m52.6m67.7m129.6m87.8m86.3m21.5m19.5m13.5m11.3m12.0m16.8m34.1m42.1m49.2m63.2m66.6m71.8m82.0m92.3m98.2m117.3m115.0m124.2m136.7m143.0m162.3m187.1m219.2m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(754.6m)29.6m(107.0m)(687.5m)(742.7m)(588.2m)(84.0m)91.6m2.1b1.2b

Depreciation and Amortization

30.5m35.0m38.2m48.4m63.3m62.3m61.4m61.4m72.4m106.9m

Inventories

(111.4m)(29.9m)7.1m(16.5m)(23.1m)(16.4m)(45.0m)(32.0m)(64.0m)

Accounts Payable

(1.2m)37.5m14.9m(49.2m)25.0m(1.7m)(11.7m)8.8m36.6m(22.8m)
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(165.3m)(365.3m)(574.2m)(176.1m)(350.2m)(129.1m)91.6m26.7m(30.9m)(308.0m)(57.2m)(124.1m)(232.5m)(391.8m)(561.9m)(198.7m)(419.7m)(513.5m)(36.1m)(72.3m)(111.8m)249.5m280.7m(10.5m)227.3m433.6m562.0m268.6m536.1m593.6m602.8m1.4b

Depreciation and Amortization

7.6m15.5m22.3m8.9m17.6m25.3m8.6m17.2m25.8m10.7m15.8m30.0m46.9m16.4m30.4m46.6m16.4m31.4m45.9m14.9m29.7m45.0m16.3m34.4m53.6m27.1m54.8m80.7m26.8m53.5m

Inventories

(17.7m)(52.1m)(66.8m)(16.9m)(34.3m)(32.4m)9.2m2.5m1.2m(4.9m)(2.6m)(9.4m)(16.1m)(4.8m)(7.8m)(11.5m)(3.6m)(22.0m)(28.6m)(8.2m)(9.4m)(24.5m)(13.1m)(25.2m)(45.3m)(27.4m)(64.4m)

Accounts Payable

(8.0m)9.6m(12.3m)(1.1m)30.1m12.1m(1.4m)(15.3m)1.4m(40.6m)978.0k7.7m(5.5m)(23.6m)(3.0m)6.3m(343.0k)(23.8m)(21.5m)717.0k14.0m6.9m2.2m12.2m23.0m(24.1m)(28.1m)(12.2m)14.3m14.7m
show all
USDQ1, 2010

Financial Leverage

1.8 x
Show all financial metrics

Vertex Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Semma TherapeuticsSeptember 03, 2019$950 m

Vertex Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

Learn more about about our premium products
SecurityScorecard logo

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals's Trends

Embed Graph

Vertex Pharmaceuticals Blogs

July 20, 2020

Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation Content Import Mon, 07/20/2020 - 09:00 Positive Phase 3 Stud…
July 16, 2020

Vertex to Announce Second-Quarter 2020 Financial Results on July 30

Vertex to Announce Second-Quarter 2020 Financial Results on July 30 Content Import Thu, 07/16/2020 - 09:02 Vertex to Announce Second-Quarter 2020 Financial Results on July 30 Jul 16, 2020 This release is a backfill from a News Wire Webcast…
June 30, 2020

Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)

Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) Content Import Tue, 06/30/2020 - 08:34 Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include K…
June 26, 2020

CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes

– If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease – – People 12 years of age and older who have two
June 25, 2020

Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice

- Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.
June 10, 2020

Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene

- KALYDECO ® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age - LONDON --(BUSINESS WIRE)--Jun.
Show more

 Vertex Pharmaceuticals Frequently Asked Questions

  • When was Vertex Pharmaceuticals founded?

    Vertex Pharmaceuticals was founded in 1989.

  • Who are Vertex Pharmaceuticals key executives?

    Vertex Pharmaceuticals's key executives are Jeffrey Leiden, Reshma Kewalramani and Sangeeta N. Bhatia.

  • How many employees does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 3,000 employees.

  • What is Vertex Pharmaceuticals revenue?

    Latest Vertex Pharmaceuticals annual revenue is $4.2 b.

  • What is Vertex Pharmaceuticals revenue per employee?

    Latest Vertex Pharmaceuticals revenue per employee is $1.4 m.

  • Who are Vertex Pharmaceuticals competitors?

    Competitors of Vertex Pharmaceuticals include Inovio Pharmaceuticals, JanOne and Reata Pharmaceuticals.

  • Where is Vertex Pharmaceuticals headquarters?

    Vertex Pharmaceuticals headquarters is located at 50 Northern Ave, Boston.

  • Where are Vertex Pharmaceuticals offices?

    Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations.

  • How many offices does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 27 offices.